Clinical Trial Update: An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of BIBF 1120 (nintedanib) in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Tumors | Phase 1 | Status: COMPLETED